Treatment of congenital fibrinogen deficiency: Overview and recent findings

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 843-848

  Tziomalos, Konstantinos ^a   Vakalopoulou, Sofia ^a   Perifanis, Vassilios ^a   Garipidou, Vassilia ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Afibrinogenemia; Cryoprecipitate; Fibrinogen concentrate; Fresh frozen plasma; Rare bleeding disorders

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ESTROGEN; FIBRIN GLUE; FIBRINOGEN; FIBRINOGEN HT; FIBRINOGENE T1; FIBRORAAS; FRESH FROZEN PLASMA; HAEMOCOMPLETTAN; HEPARIN; LEPIRUDIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; CRYOPRECIPITATE COAGULUM;

AFIBRINOGENEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; CRYOPRECIPITATE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; MENORRHAGIA; MUCOSAL BLEEDING; PREGNANCY; REVIEW; THROMBOSIS; TREATMENT DURATION; BLEEDING; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD COMPONENT THERAPY; DRUG EFFECT; FEMALE; GENETICS; MALE; MUTATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

AFIBRINOGENEMIA; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD COMPONENT TRANSFUSION; COAGULANTS; FACTOR VIII; FEMALE; FIBRINOGEN; HEMORRHAGE; HUMANS; MALE; MUTATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT OUTCOME;

EID: 73949087520     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s5305     Document Type: Review

References (60)

1. Acharya SS, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248-256.
2. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243-1252.
3. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107(1):204-206.
4. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost. 2006;4(10):2115-2129.
5. Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia. 2008;14(6):1151-1158.
6. Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus. 2008;6(Suppl 2):s39-s44.
7. Dupuy E, Soria C, Molho P, et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res. 2001;102(3):211-219.
8. Reininger AJ, Reininger CB, Spannagl M, et al. Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Thromb Haemost. 1995;74(3):853-858.
9. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest. 1986;77(4):1272-1277.
10. Soria J, Soria C, Borg JY, et al. Platelet aggregation occurs in congenital afibrinogenaemia despite the absence of fibrinogen or its fragments in plasma and platelets, as demonstrated by immunoenzymology. Br J Haematol. 1985;60(3):503-514.
11. Vakalopoulou S, Rizopoulou D, Zafiriadou E, et al. Management of acute bleeding in a patient with congenital afibrinogenaemia. Haemophilia. 2006;12(6):676-678.
12. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4(7):1634-1637.
13. Roque H, Stephenson C, Lee MJ, et al. Pregnancy-related thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol. 2004;76(3):267-270.
14. Parameswaran R, Dickinson JP, de LS, Keeling DM, Colvin BT. Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy. Haemophilia. 2000;6(6):705-708.
15. Henselmans JM, Meijer K, Haaxma R, Hew J, van der MJ. Recurrent spontaneous intracerebral hemorrhage in a congenitally afibrinogenemic patient: diagnostic pitfalls and therapeutic options. Stroke. 1999;30(11):2479- 2482.
16. Menart C, Sprunck N, Duhaut P, et al. Recurrent spontaneous intracerebral hematoma in a patient with afibrinogenemia. Thromb Haemost. 1998;79(1):241-242.
17. Koussi A, Economou M, Athanasiou-Metaxa M. Intra-abdominal hemorrhage due to a ruptured corpus luteum cyst in a girl with congenital afibrinogenemia. Eur J Pediatr. 2001;160(3):196.
18. Castaman G, Ruggeri M, Rodeghiero F. Congenital afibrinogenemia: successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive. Am J Hematol. 1995;49(4):363-364.
19. Bottini E, Pareti FI, Mari D, et al. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reports. Haematologica. 1991;76(5):431-433.
20. Schneider D, Bukovsky I, Kaufman S, Sadovsky G, Caspi E. Severe ovarian hemorrhage in congenital afibrinogenemia. Acta Obstet Gynecol Scand. 1981;60(4):431.
21. de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther. 2008;8(7):979-992.
22. Fuchs RJ, Levin J, Tadel M, Merritt W. Perioperative coagulation management in a patient with afibrinogenemia undergoing liver transplantation. Liver Transpl. 2007;13(5):752-756.
23. Oruc N, Tokat Y, Killi R, Tombuloglu M, Ilter T. Budd-Chiari syndrome in an afibrinogenemic patient: a paradoxical complication. Dig Dis Sci. 2006;51(2):378-380.
24. Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003;89(1):9-12.
25. de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost. 2002;88(2):253-258.
26. Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig. 1994;72(5):396-398.
27. Remijn JA, Wu YP, Ijsseldijk MJ, et al. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost. 2001;85(4):736-742.
28. Hanano M, Takahashi H, Itoh M, Shibata A. Coexistence of congenital afibrinogenemia and protein C deficiency in a patient. Am J Hematol. 1992;41(1):57-60.
29. Girard C, Guillot B, Biron C, et al. Digital skin necrosis in congenital afibrinogenaemia associated with hepatitis C virus infection, mixed cryoglobulinaemia and anticardiolipin antibodies. Acta Derm Venereol. 2005;85(1):56-59.
30. Kinebuchi A, Ohtsuka T, Ishida S, et al. Leg ulcer presenting in a patient with congenital afibrinogenaemia. Eur J Dermatol. 2002;12(1):70-72.
31. Rupec RA, Kind P, Ruzicka T. Cutaneous manifestations of congenital afibrinogenaemia. Br J Dermatol. 1996;134(3):548-550.
32. Shima M, Tanaka I, Sawamoto Y, et al. Successful treatment of two brothers with congenital afibrinogenemia for splenic rupture using heat- and solvent detergent-treated fibrinogen concentrates. J Pediatr Hematol Oncol. 1997;19(5):462-465.
33. Fried K, Kaufman S. Congenital afibrinogenemia in 10 offspring of uncle-niece marriages. Clin Genet. 1980;17(3):223-227.
34. Ehmann WC, al-Mondhiry H. Congenital afibrinogenemia and splenic rupture. Am J Med. 1994;96(1):92-94.
35. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4):671-684.
36. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004;10(5):593-628.
37. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370(9585):439-448.
38. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res. 2002;105(5):391-400.
39. Negrier C, Rothschild C, Goudemand J, et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost. 2008;6(9):1494-1499.
40. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005;32(3):239-246.
41. Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32(3):247-253.
42. Haberer JP, Obstler C, Samama CM, et al. Postoperative deep venous thrombosis in a woman with congenital afibrinogenaemia treated with fibrinogen concentrates. Eur J Anaesthesiol. 2008;25(6):519-521.
43. De Mattia D, Regina G, Giordano P, et al. Association of congenital afibrinogenemia and K-dependent protein C deficiency-a case report. Angiology. 1993;44(9):745-749.
44. Cronin C, Fitzpatrick D, Temperley I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol. 1988;79(1):53-54.
45. Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost. 2004;91(5):1044-1046.
46. Ra'anani P, Levi Y, Varon D, Gitel S, Martinowitz U. Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen. Harefuah. 1991;121(9):291-293.
47. De Vries A, Rosenbrg T, Kochwa S, Boss JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med. 1961;30:486-494.
48. Ehmann WC, al-Mondhiry H. Splenic rupture in afibrinogenemia: conservative versus surgical management. Am J Med. 1995;99(4):444.
49. Aygoren-Pursun E, Martinez SI, Rusicke E, et al. Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. Am J Hematol. 2007;82(4):317-320.
50. Rizk DE, Kumar RM. Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive. Am J Hematol. 1996;52(3):237-238.
51. MacKinnon HH, Fekete JF. Congenital afibrinogenemia. Vascular changes and multiple thromboses induced by fibrinogen infusions and contraceptive medication. Can Med Assoc J. 1971;104(7):597-599.
52. Neerman-Arbez M, Vu D, bu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood. 2003;101(9):3492- 3494.
53. Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol. 2000;109(2):364-366.
54. Evron S, Anteby SO, Brzezinsky A, Samueloff A, Eldor A. Congenital afibrinogenemia and recurrent early abortion: a case report. Eur J Obstet Gynecol Reprod Biol. 1985;19(5):307-311.
55. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295-307.
56. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35(4):356-366.
57. Inamoto Y, Terao T. First report of case of congenital afibrinogenemia with successful delivery. Am J Obstet Gynecol. 1985;153(7):803-804.
58. Kobayashi T, Asahina T, Maehara K, et al. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest. 1996;42(1):66-69.
59. Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol. 1991;98(7):722-724.
60. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8(3):308-321.